傳軟銀騰訊參投的晶泰科技遞美國秘密上市申請 年內籌4億至5億美元
據《路透》旗下《IFR》引述消息人士指,內地人工智能藥物研發公司晶泰科技(XtalPi)已向美國提交秘密上市申請,目標最快今年內上市,集資約4億至5億美元,現正與華興資本及中金公司等投行商討上市事宜。
報道指,晶泰科技的投資者包括軟銀集團、騰訊(00700.HK)、Google、紅杉中國及國壽股權投資公司等。
官網資料顯示,晶泰科技為一家以計算驅動創新的藥物研發科技公司,基於前沿計算物理、量子化學、人工智能與雲計算技術,為全球創新藥企提供智能化藥物研發服務,公司總部位於深圳,並在北京、波士頓設有分部,成立至今已為美國、歐洲、中國、日本的40餘家藥企提供藥物研發服務。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.